Adaptimmune Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Adaptimmune Therapeutics (ADAP) IPO Opens Up 13%
May 6, 2015 10:45 AM EDTToday's IPO for Adaptimmune Therapeutics plc (Nasdaq: ADAP) opened for trading at $19.25 after pricing 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS.
BofA Merrill Lynch, Cowen and Company and Leerink Partners LLC are acting as joint book-running... More
Adaptimmune Therapeutics (ADAP) Prices 11.25M IPO at $17/ADS
May 6, 2015 10:05 AM EDTAdaptimmune Therapeutics plc (Nasdaq: ADAP) announced the pricing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. In addition, the underwriters have been granted a 30-day option to purchase up to an additional... More
